Conference LibraryGated
Capstan Therapeutics · LNP/mRNA in vivo CAR-T (acquired by AbbVie $2.1B)
Capstan Therapeutics · in vivo CAR-T via LNP/mRNA platform · 2025 被 AbbVie 以 $2.1B 收购(per OPORD-002 P0 verify list)。是 SunVax 在 delivery modality (LNP) 维度最直接对标的 in vivo CAR-T 公司(同 modality 不同 business model)。客户 conversation 必然涉及的 reference point。
- Type
- company
- Domain
- conference
- Grade
- conference
- License
- LIGHT_HOPE_proprietary
- evidence_grade
- B
- category
- in_vivo_car_t_lnp_mrna
- status
- draft
- instance_tag
- sunvax-antibody-2025
- threat_level
- medium
- competes_dimensions
- delivery_modality,target_cell_type,in_vivo_cell_engineering
- platform_tech
- LNP / mRNA in vivo CAR-T
- acquisitions
- [object Object]
Read-only aggregated view. Conference Library is the source of record; this catalog shows provenance as-is — no ratings, no reviews.